{"id":816101,"date":"2025-02-21T02:33:10","date_gmt":"2025-02-21T07:33:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/"},"modified":"2025-02-21T02:33:10","modified_gmt":"2025-02-21T07:33:10","slug":"abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/","title":{"rendered":"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025<\/strong>\n      <\/p>\n<p align=\"center\">\n        <em>Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax\u2019s Pivotal ABTECT Phase 3 Trial<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>PARIS, France \u2013 February 21, 2025 \u2013 8:30 AM CET \u2013 <\/strong>Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET).<\/p>\n<p align=\"justify\">The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease Center at The University of Chicago. Dr. Rubin will provide expert insights into the evolving treatment landscape for ulcerative colitis (UC) and discuss expectations for Abivax\u2019s ABTECT Phase 3 trial evaluating obefazimod in adults with moderately to severely active UC. He will also explore obefazimod\u2019s potential to address critical unmet medical needs in UC treatment.<\/p>\n<p align=\"justify\">Following the presentation, attendees will have the opportunity to participate in a live Q&amp;A session with Dr. Rubin and Abivax\u2019s management team.<\/p>\n<p align=\"justify\">\n        <br \/>\n        <strong>Event Details:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong> Date: Monday, March 17, 2025<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Time: 9:00 a.m. EDT | 2:00 p.m. CET<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong> Format: Virtual webcast<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <br \/>\n        <strong>Registration Details:<\/strong>\n      <\/p>\n<p align=\"justify\">To register for the webcast and access further event details, please click on this link <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iDhxvUMhAW8-JeBw_E4ZP7OOkNuU2ZINY93Afo5Vq9wwa52J4vUKKCHd5FxeFUmtsIiz2SnbR97UztZnb03VAiOkO1P1gN5eTu7_mb6v1tXiUutFK_7_WQkTNqCKph5BngH87iFtjFdzPEEfyn-j6w==\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/lifescievents.com\/event\/abivax-3\/<\/u><\/a>.\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <br \/>\n        <strong>About Abivax <\/strong><br \/>\n        <br \/>Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax\u2019s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_4D5pjLxoQZGvtenZBPyqVYXnz-yM11fJrRpqC6Qd8TcPXB0dlsrUWe6hDkUcma_VGKot3PR6UJV_kknRJvGbw==\" rel=\"nofollow\" target=\"_blank\">www.abivax.com<\/a>. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>Patrick Malloy<br \/>SVP, Investor Relations <br \/>Abivax SA<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wEnYvR-7v088HMaiMRP7mmMi6oNEROx_SL0AL0SYVPMkb9Hv6jZkzPkPP9uyM3V_j9EJQm19P73-en4kCXMHiR6iY1JDcUpvNf-8TEjWOSpc50JkyMnRuk9siEmK1JPt\" rel=\"nofollow\" target=\"_blank\">patrick.malloy@abivax.com<\/a><br \/>+1 847 987 4878<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/Y2M4MzJiYzctNjMxMi00MjIxLWEwYzMtM2I0ZWQyNjAwZGU5LTEwMzE2ODk=\/tiny\/Abivax.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax\u2019s Pivotal ABTECT Phase 3 Trial PARIS, France \u2013 February 21, 2025 \u2013 8:30 AM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET). The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816101","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax\u2019s Pivotal ABTECT Phase 3 Trial PARIS, France \u2013 February 21, 2025 \u2013 8:30 AM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET). The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease &hellip; Continue reading &quot;Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-21T07:33:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025\",\"datePublished\":\"2025-02-21T07:33:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/\"},\"wordCount\":328,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/\",\"name\":\"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==\",\"datePublished\":\"2025-02-21T07:33:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/","og_locale":"en_US","og_type":"article","og_title":"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - Market Newsdesk","og_description":"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax\u2019s Pivotal ABTECT Phase 3 Trial PARIS, France \u2013 February 21, 2025 \u2013 8:30 AM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET). The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease &hellip; Continue reading \"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-21T07:33:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025","datePublished":"2025-02-21T07:33:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/"},"wordCount":328,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/","name":"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==","datePublished":"2025-02-21T07:33:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0OTc0MyM0MDIwNjQxNzAjMjAyMDExNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-to-host-key-opinion-leader-kol-webcast-on-march-17-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816101"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816101\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}